This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bausch Health (BHC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Bausch (BHC): Can Its 8.0% Jump Turn into More Strength?
by Zacks Equity Research
Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aurinia Pharmaceuticals (AUPH) and Bausch Health (BHC) have performed compared to their sector so far this year.
TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)
by Zacks Equity Research
TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.
TEVA to Pay $250 Million to Settle Price-Fixing Charges
by Zacks Equity Research
TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.
New Strong Buy Stocks for August 18th
by Zacks Equity Research
APP, MELI, MBWM, SHG and BHC have been added to the Zacks Rank #1 (Strong Buy) List on August 18, 2023.
Best Value Stocks to Buy for August 15th
by Zacks Equity Research
BHC, FBIZ and KB made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 15, 2023.
3 Top-Ranked Value Stocks to Buy as Recession Worries Loom
by Zacks Equity Research
Invest in companies like BHC, LSEA and TNK, which carry a low price-to-earnings ratio compared to the S&P 500 amid fresh recession worries.
Best Momentum Stock to Buy for August 8th
by Zacks Equity Research
ACLS, BHC and JHX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2023.
Best Value Stocks to Buy for August 8th
by Zacks Equity Research
BHC, GPI and UPBD made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 8, 2023.
New Strong Buy Stocks for August 8th
by Zacks Equity Research
ISNPY, SWDBY, MKL, GPI and BHC have been added to the Zacks Rank #1 (Strong Buy) List on August 8, 2023.
Bausch Health's (BHC) Q2 Earnings & Sales Beat, '23 View Raised
by Zacks Equity Research
Bausch's (BHC) second-quarter earnings and sales surpass estimates. The company increases its revenue guidance for 2023.
Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bausch Health (BHC) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 8% and 6.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Secures $600M Financing Facility, Stock Up
by Zacks Equity Research
Bausch (BHC) enters into a $600 million non-recourse financing facility with KKR to boost liquidity.
Bausch (BHC) Down on Tentative Approval to Xifaxan ANDA
by Zacks Equity Research
Bausch (BHC) declines after the FDA grants tentative approval to Norwichs ANDA for a generic version of Xifaxan.
Bausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich
by Zacks Equity Research
Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.
Bausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down
by Zacks Equity Research
Bausch (BHC) declines as it misses on earnings and sales in the first quarter.
Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bausch Health (BHC) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -30.67% and 0.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Bausch Health (BHC) Q1 Earnings Expected to Decline
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Bausch Health (BHC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.
Bausch Health's (BHC) Q4 Earnings & Sales Beat, Shares Up
by Zacks Equity Research
Bausch (BHC) reports an increase in earnings and sales in the fourth quarter as the company???s business revives in the second half.
Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 10.87% and 3.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Perion Network and West Fraser Timber have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Perion Network and West Fraser Timber are part of the Zacks Bull and Bear of the Day article.